Liver carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The expression of PRDX2 at both mRNA and protein levels was examined by q‑RT‑PCR, western blotting and immunohistochemical assessment in HCC tissues and cell line HCCLM3.
|
30747220 |
2019 |
Liver carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the link between Prx2 and CSC stemness through regulation of ROS levels in hepatocellular carcinoma (HCC) cells.
|
30611866 |
2019 |
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Moreover, C<sub>12</sub>-PRP displayed no cytotoxicity against human liver carcinoma HepG2 and human embryonic kidney HEK-293 cell lines.
|
29437631 |
2018 |
Liver carcinoma
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Prx II is FoxM1-dependently-expressed antioxidant in HCC and function as an enhancer of Ras(G12V) oncogenic potential in hepatic tumorigenesis through activation of ERK/FoxM1/cyclin D1 cascade.
|
26500057 |
2016 |
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
We found that Torin-2 effectively suppressed the growth and survival of HCC cell lines, demonstrated by reduced proliferation and a high rate of apoptosis.
|
26239364 |
2015 |
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
TSA selectively induced uc002mbe.2 in four studied HCC cell lines.
|
23643933 |
2013 |
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS.
|
21472284 |
2012 |
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
We analyzed the effects of TSA, a specific and potent HDAC inhibitor, on the human hepatoma cell lines HepG2 and Huh-7.
|
12494463 |
2003 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Designing therapeutics targeting Prx2 may offer a novel strategy for developing treatments for prostate cancer, including castration-resistant prostate cancer, which is dependent on AR signaling.
|
21539911 |
2011 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.
|
17566973 |
2007 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Ectopic expression of a partial sequence of PTX1 (Met84 - Leu225) as a VP22-fusion protein in prostate cancer cell line, PC-3, induced cellular senescence.
|
16989575 |
2006 |
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Effects of PTX1 expression on growth and tumorigenicity of the prostate cancer cell line PC-3.
|
12932305 |
2003 |
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Molecular cloning, expression, localization, and gene organization of PTX1, a human nuclear protein that is downregulated in prostate cancer.
|
11445006 |
2001 |
Esophageal Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
The expression levels of ZNF667-AS1 and ZNF667 were significantly reversed by treatment with 5-Aza-dC and TSA in esophageal cancer cell lines.
|
31804468 |
2019 |
Malignant neoplasm of esophagus
|
0.330 |
Biomarker
|
disease |
BEFREE |
The expression levels of ZNF667-AS1 and ZNF667 were significantly reversed by treatment with 5-Aza-dC and TSA in esophageal cancer cell lines.
|
31804468 |
2019 |
Esophageal Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
The expression level of CTC-276P9.1 in esophageal cancer cells was significantly reversed by treatment with 5-Aza-dC and TSA.
|
29524086 |
2018 |
Malignant neoplasm of esophagus
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The expression level of CTC-276P9.1 in esophageal cancer cells was significantly reversed by treatment with 5-Aza-dC and TSA.
|
29524086 |
2018 |
Esophageal Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
We reported 4 differentially expressed proteins involved in the pathological process of esophageal cancer, such as annexinA1 (ANXA1), peroxiredoxin-2 (PRDX2), transgelin (TAGLN) andactin-aortic smooth muscle (ACTA2).
|
28392898 |
2017 |
Malignant neoplasm of esophagus
|
0.330 |
Biomarker
|
disease |
BEFREE |
We reported 4 differentially expressed proteins involved in the pathological process of esophageal cancer, such as annexinA1 (ANXA1), peroxiredoxin-2 (PRDX2), transgelin (TAGLN) andactin-aortic smooth muscle (ACTA2).
|
28392898 |
2017 |
Esophageal Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
Comparative proteomic analysis of esophageal squamous cell carcinoma.
|
15986332 |
2005 |
Malignant neoplasm of esophagus
|
0.330 |
Biomarker
|
disease |
CTD_human |
Comparative proteomic analysis of esophageal squamous cell carcinoma.
|
15986332 |
2005 |
Down Syndrome
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Moreover, while up-regulation of Prx II appears to provide evidence for the existence of compensatory response in increased cell loss, up-regulation of Prx VI may be used to discriminate PD from AD as well as DS.
|
12650976 |
2003 |
Down Syndrome
|
0.330 |
AlteredExpression
|
disease |
LHGDN |
This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1.
|
12943237 |
2003 |
Down Syndrome
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1.
|
12943237 |
2003 |
Down Syndrome
|
0.330 |
AlteredExpression
|
disease |
LHGDN |
Moreover, while up-regulation of Prx II appears to provide evidence for the existence of compensatory response in increased cell loss, up-regulation of Prx VI may be used to discriminate PD from AD as well as DS.
|
12650976 |
2003 |